Variability in pharmacological response to metformin treatment
Abstract
Background: According to the Slovenian guidelines, metformin, an oral antidiabetic drug, is a drug of choice for the treatment of type 2 diabetes. Additionally, metformin is paving its way in polycystic ovary syndrome (PCOS) treatment, although the drug has not (yet) been officially indicated to treat PCOS. Studies have shown that metformin improves clinical and biochemical features of PCOS as well as the rate of ovulation and consequently the likelihood of conception in PCOS women. At the same dosage regimen, pharmacological effects of metformin show interindividual variability in metformin response; efforts have been made to at least partly explain the variability with polymorphic variants in genes related to metformin pharmacodynamics and pharmacokinetics.
Conclusions: The results of the current studies indicate that polymorphic variants in genes related to metformin pharmacodynamics and pharmacokinetics may contribute to the interindividual variability in pharmacological response to metformin treatment in diabetic as well as in PCOS patients.
Downloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
